(NASDAQ: IMUX) Immunic's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Immunic's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast IMUX's revenue for 2027 to be $27,957,640,654, with the lowest IMUX revenue forecast at $191,635,072, and the highest IMUX revenue forecast at $79,562,091,018. On average, 4 Wall Street analysts forecast IMUX's revenue for 2028 to be $49,443,477,474, with the lowest IMUX revenue forecast at $7,768,885,819, and the highest IMUX revenue forecast at $114,265,286,206.
In 2029, IMUX is forecast to generate $101,503,540,221 in revenue, with the lowest revenue forecast at $14,765,482,298 and the highest revenue forecast at $186,077,654,912.